Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03652233 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Low accrual

Conditions

Recurrent Squamous Cell Carcinoma of the Head or Neck
Metastatic Squamous Cell Carcinoma of the Head or Neck
Squamous Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Afatinib

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]
[object Object]